• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Sweden·Basic Materials·AXIC-A.ST
Share

aXichem AB Stocks

SEK 1.74Last Updated 26.10.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

SEK 12.97M

SEK 1.74
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

aXichem AB is a biotechnology firm, established in 2007 and headquartered in Malmö, Sweden, that specializes in creating natural analogue compounds. The company offers aXivite, a capsaicin analogue solution designed for various dietary health applications. Another key product, aXiphen-bio, functions as a biological repellent, providing antifouling protection for marine vessels and installations, and managing pests in agriculture, forestry, and for safeguarding cable infrastructure both within buildings and underground. Additionally, aXiphen-feed is developed to boost the health of poultry, including chickens and hens, as well as swine, such as pigs and piglets.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.10.2026 08:30

Wall Street has identified Broadcom as a major beneficiary of Anthropic's IPO. Who else stands to gain?

28.10.2026 08:01

"Too Big a Chicken": McDonald's Partners Deem the New Menu a Failure

28.10.2026 07:01

Healthcare stocks have become a bet against AI. Should you buy them?

28.10.2026 03:18

"The conditions for a rebound are ripe": Stocks rise for a second day ahead of big tech earnings reports

28.10.2026 03:13

Oracle is expanding its partnership with OpenAI and integrating Google chips into its infrastructure

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026